Pharmaceuticals, Biotechnology & Life Sciences

Insider buying shows confidence in ImmunityBio’s growth—executives buy low, sell high and exercise options amid Anktiva sales and new approvals.

Theravance CEO sells 75k shares for tax planning: insider moves, market sentiment, and long‑term growth prospects explained.

Vir Biotechnology insiders, led by Sabatini Brent, are buying large RSUs and options, signaling confidence in upcoming vaccine and partnership catalysts.

MapLight insiders sell shares to cover RSU taxes, while executives buy back—investors see modest supply pressure, but potential upside from Q3 2026 clinical data.

Insider buying by Halozyme’s COO signals confidence in its hyaluronidase pipeline and future growth, despite a recent share price dip.

Insider sale by Ocular Therapeutix’s chief medical officer shows routine tax‑cover, yet heightened social‑media buzz signals investors watch for future moves and clinical milestones.

Insider buy of 2,500 shares in Madrigal Pharmaceuticals signals growing confidence; learn how this modest move hints at future upside despite a negative P/E.

Prime Medicine insider buys 375k+ options on PRMI’s $3.83 stock, signaling confidence amid volatility and a potential rally ahead of J.P. Morgan talks.

Rigel Pharmaceuticals insider moves: CEO sells, execs buy. Investor take‑away: tactical trades hint at upcoming earnings, pipeline, and regulatory milestones.

Insider buying sprees at Niagen Bioscience show exec confidence—are investors poised for a long‑term upside? Explore what this means for your portfolio.